Lumos Pharma — NewLink Genetics — Q1 2017 Earnings Presentation
9 slides from Lumos Pharma's earnings presentation, May 4, 2017
Slide 1: First Quarter 2017 Results
NewLink Genetics Corporation Nasdaq: NLNK May 4, 2017 First Quarter 2017 Results
Slide 2: Agenda
Agenda 2 Introduction Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates / Guidance on Timing of Data Nicholas N. Vahanian, M.D., President & CMO First Quarter 2017 Financial Results Mr. Henneman
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w
Slide 4: Q1 Takeaways
Q1 Takeaways Emerging clinical data are validating the IDO pathway as central to immunosuppression IDO pathway inhibition has the potential to enhance patient outcomes when used in combination with other cancer therapies NewLink has two distinct types of IDO pathway inhibitors in the clinic –
Slide 5: Best Response by Patient: Non-ocular Versus Ocular
Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Best Response by Patient 5 Distinct Difference in Non-ocular Versus Ocular Patients 80% 100% 40% 60% 0% 20% –40% –20% –60% –80% –100%
Slide 6: Change in Tumor Volume Over Time: Durable and Ongoing Responses
Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Change in Tumor Volume Over Time 6 Durable and Ongoing Responses PR, partial response. Note: 1 patient was unevaluable for response d
Slide 7: Anticipated Highlights for 2017 Clinical Programs
Anticipated Highlights for 2017 Clinical Programs Metastatic castration resistant prostate cancer: – Abstract 3066: Randomized placebo-controlled Phase 2 clinical trial data to be presented at ASCO on Monday, June 5, 2017, 9:00 AM ET-12:30 PT ET Metastatic pancreatic cancer: – Indoximod in combi
Slide 8: First Quarter 2017 Financial Results
First Quarter 2017 Financial Results Cash and Equivalents $118.2 million Debt ~$0.5 million YE 2017 Cash (Projected) ~$75 million Quarterly Negative Cash-Flow ~$13 million Shares Outstanding 29.2 million Market Capitalization ~$500 million Headcount 127 8 Major 2017 YE Cash Projection Assumptions: T
Slide 9: Q & A
9 Q & A